Clinical Trial Update: MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of MK-2206 in breast cancer was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Status: TERMINATED | Results posted: 2017-08-01